NOUS-209
AXP000163.1 · Cancer vaccine
- Platform
- great ape adenovirus (GAd20) prime with MVA boost
- Originator
- Nouscom
- Sponsor
- Nouscom
Names
| Name | Type | Source |
|---|---|---|
| NOUS-209 | preferred name, code | curator, press |
| GAd-209-FSP | code | ncit |
| GAd20-209-FSP | code | ncit |
| MVA-209-FSP | code | ncit |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- great ape adenovirus 20
- Strain
- GAd20
- Replication
- non replicating
- Modifications
- non-replicating great ape adenovirus encoding 209 shared frameshift peptide neoantigens; boosted by modified vaccinia Ankara (MVA-209-FSP)
- Transgenes
- 209 shared frameshift peptide neoantigens
- Route
- intramuscular
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05078866 | Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients | Active not recruiting | Phase 1/2 | 2022-11-10 | 2025-04-16 | 45 | Colorectal Carcinoma; Lynch Syndrome |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Active not recruiting | Phase 1/2 | 2019-10-21 | 2026-10-30 | 115 | Solid Tumor, Adult |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41545594 | Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. | Nature medicine | 2026 | cited by trial NCT05078866 |
| PMID 42662364 | Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report. | Journal of immunotherapy and precision oncology | 2026 | cited by trial NCT04041310 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41232028 | NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome. | Molecular cancer therapeutics | 2026 | name in title: NOUS-209 |
| PMID 42108525 | Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers' Precancer Lesions with Microsatellite Instability. | Cancer prevention research (Philadelphia, Pa.) | 2026 | name in title: NOUS-209 |
| PMID 38543959 | Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine. | Vaccines | 2024 | name in title: NOUS-209 |
| PMID 39706858 | Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer. | NPJ precision oncology | 2024 | name in abstract: NOUS-209 |
| PMID 32690723 | A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability. | Cancer research | 2020 | name in abstract: NOUS-209 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA294638 | Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome | UNIVERSITY OF TX MD ANDERSON CAN CTR | VILAR SANCHEZ, EDUARDO | 2026–2026 | name in abstract: NOUS-209 |
Notes
Heterologous prime-boost of a great ape (gorilla) adenovirus GAd20-209-FSP prime and an MVA-209-FSP boost, both encoding 209 shared frameshift peptide neoantigens of microsatellite-unstable tumours. Marketed as one product, so entered as one program per spec section 1; the poxvirus boost is recorded here rather than as its own entry. Phase 1b/2 in Lynch syndrome carriers and in dMMR/MSI-high tumours with pembrolizumab. NCIt holds the two components separately (GAd-209-FSP C162805, MVA-209-FSP C162806), so no single NCIt code is recorded.
How to cite
NOUS-209 (AXP000163.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000163.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.